Olanzapine: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Olanzapine. Educational only — not medical advice.

Reported adverse reactions

Reaction	Highest frequency reported*
Somnolence	35%
Dry mouth	22%
Dizziness	18%
Asthenia	15%
Accidental injury	12%
Insomnia	12%
Constipation	11%
Dyspepsia	11%
Personality disordera	8%
Rhinitis	7%
Speech disorder	7%
Increased appetite	6%
Tremor	6%
Fever	6%
Abnormal gait	6%
Cough increased	6%
Increased salivation	6%
Back pain	5%
Ecchymosis	5%
Weight gain	5%

*Highest percentage across placebo-controlled trial tables summarized in current labeling.

Labeled uses

1.1 SchizophreniaOral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies (14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I ManiaZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to t…

Source: FDA labeling via NIH DailyMed (set 66ef201f…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.